Director of Neuroendocrine Tumor Center and Director of Department of Neuroendocrine Tumor, Fudan University Shanghai Cancer Center; Chief Physician, Professor, Doctoral Supervisor; Chief Expert, Neuroendocrine Tumor Multidisciplinary Team
Consultant of Jiahui International Cancer Center

Education
Graduated from West China University of Medical Sciences, School of Clinical Medicine, in 1994
Twice a visiting scholar at the Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, during postgraduate studies (2000–2002)
Received MD in Gastroenterology from the First Affiliated Hospital of Sun Yat-sen University in 2002
Postdoctoral research at the Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Magdeburg, Germany (2002–2004), focusing on the pathogenesis of gastrointestinal tumors
Studied neuroendocrine tumor diagnosis and treatment at Churchill Hospital, University of Oxford, and Royal Free Hospital / King's College Hospital, University of London (November–December 2011)

Clinical Expertise
Diagnosis and treatment of various neuroendocrine tumors, including:
-Neuroendocrine tumors of various sites and types: gastric and intestinal NETs, pancreatic NETs, gastrinoma, insulinoma, glucagonoma, carcinoid syndrome, ACTHoma, VIPoma, carcinoid, atypical carcinoid, small cell carcinoma, large cell neuroendocrine carcinoma, pheochromocytoma, paraganglioma, medullary thyroid carcinoma, cutaneous Merkel cell carcinoma, etc.
-Hereditary neuroendocrine tumors: multiple endocrine neoplasia types 1, 2 and 4 (MEN1/2/4), von Hippel-Lindau (VHL) syndrome, neurofibromatosis type 1 (NF1), etc.

Academic Contributions & Appointments
Since 2010, pioneered the field of neuroendocrine tumors (NEN) in China and established a comprehensive clinical diagnosis and treatment system, including a multidisciplinary team covering all NEN-related disciplines, dedicated medical groups, wards and clinics, with an annual outpatient volume of 4,500 visits
Selected in 2015 as the only Asian member of the ENETS Advisory Board, European Neuroendocrine Tumor Society
In 2015, the Chinese Study Group for Neuroendocrine Tumor (CSNET) under the Pancreatic Cancer Committee of China Anti-Cancer Association was established, and she served as its first group leader
Invited in 2019 as an editorial board member of Neuroendocrinology, the official journal of ENETS
Invited in 2020 as a member of the Medical Advisory Board of the International Neuroendocrine Cancer Alliance (INCA)
Invited in 2021 as a member of the Neuroendocrine and Endocrine Tumors Group of the European Society for Medical Oncology (ESMO), the first and only Chinese expert to serve on this committee
Initiated the establishment of the Neuroendocrine Tumor Committee of the China Anti-Cancer Association in 2022 and will serve as its first chairman
Member, Chinese Medical Association
Vice Chairman, Tumor Endocrinology Committee, China Anti-Cancer Association
Deputy Head, Gastrointestinal Hormone and Neuroendocrine Tumor Group, Digestive Disease Branch, Chinese Medical Association
Vice Chairman, Pancreatic Neuroendocrine Tumor Committee, Pancreatic Disease Branch, Chinese Medical Doctor Association
Standing Committee Member, Neuroendocrine Tumor Branch, China International Exchange and Promotive Association for Medical and Health Care
Member, Rare Tumor Expert Committee, Chinese Society of Clinical Oncology (CSCO)
Senior Editorial Board Member, Journal of Neuroendocrinology; Editorial Board Member, Journal of Pancreatology; Editorial Board Member, China Oncology; Corresponding Editorial Board Member, Chinese Journal of Digestion

Research Achievements
Published more than 40 SCI-indexed clinical research papers, over 30 as corresponding author or co-corresponding/first author, covering epidemiology, molecular markers, drug therapy, imaging diagnosis, and pathological grading and staging
A multicenter collaborative study on modified staging of pancreatic neuroendocrine tumors was published in the top oncology journal J Clin Oncol
As CSNET group leader, initiated and participated in the development of two CSNET expert consensuses, published in Int J Oncol in 2016–2017
As a major contributor, participated in the development of the Expert Consensus on Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Tumors (Digestive Disease Branch, Chinese Medical Association) and the Guidelines for Diagnosis and Treatment of Pancreatic Neuroendocrine Tumors (Pancreatic Surgery Group, Surgery Branch, Chinese Medical Association)
As chief editor, led the development of the first Integrated Diagnosis and Treatment Guidelines for Neuroendocrine Tumors of the China Anti-Cancer Association
As a member of the ENETS Advisory Board, participated in the development of the 2017 updated ENETS clinical practice guidelines for neuroendocrine tumors